Chronic cocaine administration reduces phospholipase A2 activity in rat brain striatum

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 5-6, 2002, Pages 479-483

  Ross, B M ^a   Turenne, S D ^b  

^a UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; HALOPERIDOL; PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; COCAINE DEPENDENCE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; MALE; NEUROCHEMISTRY; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0036586668     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2002.0385     Document Type: Article

References (33)

1. 2 and signal transduction. Brain Res Rev 1995; 21: 152-161.
2. 2: its role in adaptive neuronal plasticity. Cell Mol Life Sci 2000; 57: 1542-1550.
3. Berg K. A., Maayani S., Goldfarb J., Scaramellini C., Leff P., Clarke W. P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998; 54: 94-104.
4. Chio C. L., Drong R. E., Riley D. T., Gill G. S., Slightom J. L., Huff R. M. D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269: 11813-11819.
5. 2. J Neurochem 1995; 64: 2765-2772.
6. 2 dopamine receptor expressed in CHO cells FEBS Lett 1993; 324: 81-86.
7. Seeman P., Niznik H. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990; 4: 2737-2744.
8. Chen N., Reith M. E. Structure and function of the dopamine transporter. Eur J Pharmacol 2000; 405: 329-339.
9. Reith M. E., Xu C., Chen N. H. Pharmacology and regulation of the neuronal dopamine transporter. Eur J Pharmacol 1997; 324: 1-10.
10. Ingram S. L., Amara S. G. Arachidonic acid stimulates a novel cocaine-sensitive cation conductance associated with the dopamine transporter. J Neurosci 2000; 20: 550-557.
11. 2 mechanisms in the development of stimulant sensitisation. J Pharm Exp Ther 1993; 276: 1244-1256.
12. Schwarz R. D., Uretsky N. J., Bianchine J. R. Prostaglandin inhibition of amphetamine-induced circling in mice. Psychopharmacology (Berlin) 1982; 78: 317-321.
13. 2 activity is selectively decreased in the striatum of chronic cocaine users. J Neurochem 1996; 67: 2620-2623.
14. 2 activities in brain of patients with schizophrenia. Brain Res 1999; 821: 407-413.
15. Wilson J. M., Levey A. I., Bergeron C., Kalsinsky K., Ang L., Peretti F., Adams V. I., Smialek J., Anderson W. R., Shannak K., Deck J., Niznik H. B., Kish S. J. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996; 40: 428-439.
16. Peet M., Brind J., Ramchand C. N., Shah S., Vankar G. K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243-251.
17. Renshaw P. R., Daniels S., Lundahl L. H., Rogers V., Lukas S. E. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology (Berlin) 1999; 142: 132-138.
18. Ross B. M., Kish S. J. Characterisation of lysophospholipid metabolising enzymes in human brain. J Neurochem 1994; 63: 1839-1848.
19. Ross B. M., Mamalias N., Moszczynska A., Rajput A. H., Kish S. J. Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease. Neuroscience 2001; 102: 899-904.
20. 2 activity in human brain. J Neurochem 1995; 64: 2213-2221.
21. Cejtin H. E., Parsons M. T., Wilson L. Cocaine use and its effect on umbilical prostacyclin production. Prostaglandin 1990; 40: 249-257.
22. 2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp Ther 2001; 296: 1074-1084.
23. 2. Adv Second Messenger Phosphoprotein Res 1993; 28: 81-89.
24. 2 in agonist-stimulated arachidonic acid release in membranes isolated from bovine iris sphincter smooth muscle. Membr Biochem 1993; 10: 29-42.
25. Breier A., Su T. P., Saunders R., Carson R. E., Kolachana B. S., de Bartolomeis A., Weinberger D. R., Weisenfeld N., Malhotra A. K., Eckelman W. C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569-2574.
26. 2 signaling in rat basal ganglia circuits. Brain Res 2001; 896: 96-101.
27. 2 activity in the brain of rats. Eur Arch Psychiatry Clin Neurosci 1995; 245: 179-182.
28. 2+-dependent, and carbachol-mediated arachidonic acid release from rat brain cortex membrane. J Neurochem 1991; 57: 1198-1206.
29. 2-activating protein and by activation of phospholipase C and D. J Biol Chem 2001; 276: 5467-5475.
30. 2-cyclooxygenase pathways in inflammation. J Leukoc Biol 1999; 66: 535-541.
31. Ross B. M. Brain and blood phospholipase activity in psychiatric disorders. In: Peet M., Glen I., Horrobin D. F., eds. Phospholipid Spectrum Disorder in Psychiatry. Carnforth: Marius Press, 1999; 23-30.
32. Ross B. M., Brooks R. J., Lee M., Kalasinsky K. S., Vorce S. P., Seeman M., Fletcher P. J., Turenne S. D. Cyclooxygenase inhibitor modulation of dopamine-related behaviours, submitted.
33. Zhang L., Reith M. E. Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur J Pharmacol 1996; 315: 345-354.